ITM Set to Present at the 44th Annual J.P. Morgan Healthcare Conference
Garching / Munich, Germany – November 11, 2025 – ITM, a leading radiopharmaceutical biotech company, today announced that its Chief Executive Officer Dr. Andrew Cavey and Chief Financial Officer Dr. Klaus Maleck will take part in the 44th Annual J.P. Morgan Healthcare Conference, scheduled to run from January 12 to 15, 2026, in San Francisco, California. On Tuesday, January 13, 2026, from 8:00 AM to 8:25 AM PST, Dr. Cavey will present a corporate overview at the Westin St. Francis Hotel.
For more information, please contact:
Investor Relations
Ben Orzelek
Telephone: +49 89 329 8986 1009
Email:
Corporate Communications
Kathleen Noonan/Julia Westermeir
Telephone: +49 89 329 8986 1500
Email:
About ITM Isotope Technologies Munich SE
ITM, a leading radiopharmaceutical biotech firm, is dedicated to delivering a next-generation lineup of radiopharmaceutical treatments and diagnostic tools for hard-to-treat tumors. Our mission is to address the needs of cancer patients, clinicians, and partners through excellence in the development, manufacturing, and global distribution of medical radioisotopes. Guided by the core principle of enhancing patient benefits in all we do, ITM advances an extensive precision oncology pipeline—featuring multiple Phase 3 studies—that combines the company’s high-quality radioisotopes with various targeting molecules. By leveraging our two decades of groundbreaking radiopharma expertise, key industry standing, and well-established global network, ITM works to offer patients more effective targeted therapies to boost clinical results and quality of life.
Attachment
